In a groundbreaking first, psilocybin is entering gastroenterology. Dr. Erin Mauney leads a pioneering study exploring how psychedelic therapy could transform treatment for millions suffering from treatment-resistant Irritable Bowel Syndrome, offering new hope for gut-brain disorders.
Dr Vincent Maida discusses his discoveries and pioneering research in the area of using Topical Cannabis-Based Medicines (TCBM) for integumentary and wound management.
Peter Jackson, Executive Director of the AMR Centre, describes new initiatives and partnerships that point the way forward for the UK’s antimicrobial resistance response.
Prof Colin J Suckling OBE DSc FRSE from the Department of Pure & Applied Chemistry, details the ‘why’ and ‘what’ of academic drug discovery research at the University of Strathclyde, as well as his thoughts on the value of a chemistry degree.
With attention turning in the U.S. and elsewhere to how cannabis businesses are banked, John Binns, Partner at BCL Solicitors LLP, gets into the weeds of how UK banks have been addressing the issue, as well as the prospects for improvement.
Investment Manager at the Ministry of Foreign Affairs of Denmark, Michael Prytz, charts the rapid development of the medical cannabis market in Europe and provides a look at the Danish model in this vein.
Dr Nikos Xynos, PhD in Pharmaceutical Sciences/Natural Products Chemistry and MD a Nomad Labs, explores the various pathways to cannabinoid extraction, refining and purification technologies.
